Steward Financial Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Steward Financial Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$2K	Buy	+15	New	+$2.86K	﹤0.01%	918
2023 Q2	–	Sell	-12	Closed	-$2K	–	437
2023 Q1	$2K	Buy	12 +8	+200%	+$1.68K	﹤0.01%	468
2022 Q4	$0	Buy	+4	New	+$853	﹤0.01%	531
2022 Q3	–	Sell	-4	Closed	–	–	104
2022 Q2	$0	Buy	+4	New	+$567	﹤0.01%	954

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Steward Financial Group's ALNY Position: Q3 2023 in Review

Steward Financial Group opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2023: 15 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #918 among its holdings. This is a return to the name: Steward Financial Group previously reported a position in ALNY as recently as Q1 2023.

Steward Financial Group first reported a position in ALNY in Q2 2022 and has held it in 4 quarters since. 453 funds tracked by Wall St. Rank hold ALNY as of Q3 2023.

Steward Financial Group held 15 shares of Alnylam Pharmaceuticals worth $2K as of Q3 2023.
Alnylam Pharmaceuticals was a new Steward Financial Group position in Q3 2023.
Alnylam Pharmaceuticals made up ﹤0.01% of Steward Financial Group's portfolio in Q3 2023, its #918 holding.
Steward Financial Group first reported a position in Alnylam Pharmaceuticals in Q2 2022 and has held it in 4 quarters since.
453 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2023.

Based on Steward Financial Group's 13F filing for Q3 2023, filed 23 Oct 2023.